腹壁疝修补中生物或生物合成补片的应用现状
该回顾性队列研究基于密歇根州 statewide 临床注册数据,纳入 2021 年至 2023 年接受补片腹壁疝修补的 10 838 例成人患者,发现 10.8% 使用生物或生物合成补片,其中 87.1% 为清洁切口、88.5% 为择期手术;伤口污染、急诊手术、腹腔镜或机器人入路、较大疝宽度及肌筋膜松解与使用增加相关,提示当前实践中近九成生物补片用于清洁择期病例的适宜性存疑。
要点
- 10.8% 的补片腹壁疝修补使用生物或生物合成补片,其中近九成用于清洁切口择期手术。
- 伤口污染程度越高,使用生物或生物合成补片的比值比越大(脏/感染伤口 aOR 36.22)。
- 急诊手术、腹腔镜或机器人入路、较大疝宽度及肌筋膜松解也与生物补片使用增加相关。
核心结论
- 约十分之一的补片腹壁疝修补使用生物或生物合成补片,但近 90% 的应用发生在清洁切口的择期手术中,其适宜性存疑。
研究设计与样本
- 回顾性队列研究,利用密歇根州全州临床注册数据,纳入 2021 年 1 月 1 日至 2023 年 12 月 31 日接受补片腹壁疝修补的成人患者。
- 共纳入 10 838 例患者,平均(标准差)年龄 55.7(14.0)岁,女性 4619 例(42.6%)。
主要发现
- 1174 例(10.8%)使用生物或生物合成补片,9664 例(89.2%)使用合成补片。
- 使用生物或生物合成补片的 1174 例中,1023 例(87.1%)为清洁伤口分类,1039 例(88.5%)为择期手术。
关键数值与推荐
- 多变量 logistic 回归显示,伤口污染与生物或生物合成补片使用增加相关:清洁-污染 aOR 2.17(95%CI 1.62-2.89),污染 aOR 2.95(95%CI 1.63-5.34),脏或感染 aOR 36.22(95%CI 12.20-107.56)。
- 急诊或紧急手术优先级 aOR 1.69(95%CI 1.33-2.16),腹腔镜或机器人入路 aOR 1.31(95%CI 1.15-1.50),疝宽度每增加 1 厘米 aOR 1.03(95%CI 1.01-1.04),肌筋膜松解 aOR 2.10(95%CI 1.64-2.70)。
临床怎么用
- 临床中应审慎评估生物或生物合成补片在清洁切口择期腹壁疝修补中的使用指征。
- 对于污染或感染伤口,生物或生物合成补片的使用增加符合其原始设计场景,但仍需结合患者具体情况判断。
局限性
- 本研究为回顾性队列研究,仅基于密歇根州注册数据,结果外推需谨慎。
- 原文未报告生物或生物合成补片使用的具体适应证、补片类型及长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Originally developed for use in contaminated fields, there is growing evidence against the use of biologic and biosynthetic mesh in ventral hernia repair. However, its prevalence and patterns of use in current practice are largely unknown. OBJECTIVES: To describe the prevalence of biologic and biosynthetic mesh use in ventral hernia repair and to identify factors associated with its use. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used a statewide clinical registry in Michigan to identify adults who underwent mesh-based ventral hernia repair between January 1, 2021, and December 31, 2023. Data analysis was performed from February to May 2024. EXPOSURES: Use of biologic or biosynthetic mesh vs synthetic mesh. MAIN OUTCOMES AND MEASURES: The main outcome was use of biologic or biosynthetic mesh, abstracted directly from the operative report. Multivariable logistic regression was used to identify factors associated with use of biologic or biosynthetic mesh. RESULTS: A total of 10 838 patients (mean [SD] age, 55.7 [14.0] years; 4619 [42.6%] female) who underwent mesh-based ventral hernia repair were identified, among whom 1174 repairs (10.8%) were performed with biologic or biosynthetic mesh and 9664 (89.2%) were performed with synthetic mesh. Of the 1174 cases using biologic or biosynthetic mesh, 1023 (87.1%) had a clean wound classification and 1039 (88.5%) were performed electively. In multivariable logistic regression, wound contamination was associated with increased odds of biologic or biosynthetic mesh use (clean-contaminated: adjusted odds ratio [aOR], 2.17 [95% CI, 1.62-2.89]; contaminated: aOR, 2.95 [95% CI, 1.63-5.34]; dirty or infected: aOR, 36.22 [95% CI, 12.20-107.56]). Other operative factors associated with increased odds of biologic or biosynthetic mesh use included urgent or emergent surgical priority (aOR, 1.69 [95% CI, 1.33-2.16]), laparoscopic or robotic approach (aOR, 1.31 [95% CI, 1.15-1.50]), larger hernia width (aOR, 1.03 [95% CI, 1.01-1.04] per centimeter), and use of myofascial release (aOR, 2.10 [95% CI, 1.64-2.70]). CONCLUSIONS AND RELEVANCE: In this large cohort of patients undergoing ventral hernia repair, 1 in 10 mesh-based repairs was performed with biologic or biosynthetic mesh. Although urgent or emergent repair and wound contamination were associated with increased odds of biologic or biosynthetic mesh use, nearly 90% of biologic and biosynthetic mesh use occurred in elective repairs with clean wound classifications. These results raise questions regarding the appropriateness of its application in current practice.
引用
- Mullens CL, Schoel L, McGee MF, et al. Use of Biologic and Biosynthetic Mesh for Ventral Hernia Repair in Current Practice. JAMA Surg. 2025. PMID: 39661349. doi:10.1001/jamasurg.2024.5293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。